Volume 4.27 | Jul 16

Pulmonary Cell News 4.27 July 16, 2015
Pulmonary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   PULCN on Twitter
 
TOP STORY
A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC
Scientists describe the discovery and biological activity of a cyclopropylamine containing inhibitor of lysine demethylase 1 (LSD1), GSK2879552. A proliferation screen of cell lines representing a number of tumor types indicated that small cell lung carcinoma (SCLC) is sensitive to LSD1 inhibition. [Cancer Cell] Abstract
Learn More: Model the Human Airway at the Air-Liquid Interface
 
PUBLICATIONS (Ranked by impact factor of the journal)
Pulmonary Administration of Phosphoinositide 3-Kinase Inhibitor Is a Curative Treatment for Chronic Obstructive Pulmonary Disease by Alveolar Regeneration
The authors directed their attention to phosphoinositide 3-kinase (PI3K)-Akt signaling and examined whether PI3K inhibitors display pulmonary alveolus regeneration. Three PI3K inhibitors with different PI3K subtype specificities were tested for the differentiation-inducing effect on human alveolar epithelial stem cells, and Wortmannin demonstrated the most potent differentiation-inducing activity. [J Control Release] Abstract

miR-17 Overexpression in Cystic Fibrosis Airway Epithelial Cells Decreases Interleukin-8 Production
miR-17 regulates interleukin-8 and its expression was decreased in adult cystic fibrosis bronchial brushings, βENaC-transgenic mice and bronchial epithelial cells chronically stimulated with Pseudomonas-conditioned medium. [Eur Respir J] Abstract

Epinephrine Activation of the β2-Adrenoceptor Is Required for IL-13-Induced Mucin Production in Human Bronchial Epithelial Cells
Scientists asked whether β2-adrenoceptor signaling in normal human airway epithelial cells affected mucin production in response to IL-13. This cytokine markedly increased mucin production, but only in the presence of epinephrine. [PLoS One] Full Article

Effective Apical Infection of Differentiated Human Bronchial Epithelial Cells and Induction of Proinflammatory Chemokines by the Highly Pneumotropic Human Adenovirus Type 14p1
The apical infection of differentiated primary human bronchial epithelial cells with the pneumotropic and virulent type human adenovirus (HAdV)-B14p1 was investigated in comparison to the less pneumotropic HAdV-C5 as a control. [PLoS One] Full Article

LUNG CANCER

Homoharringtonine Induces Apoptosis and Inhibits STAT3 via IL-6/JAK1/STAT3 Signal Pathway in Gefitinib-Resistant Lung Cancer Cells
Scientists investigated the antitumor effect of homoharringtonine, a natural compound extracted from Cephalotaxus harringtonia, on Gefitinib-resistant non-small cell lung cancer cell lines in vitro and in vivo. [Sci Rep] Full Article

Blocking the Epithelial-to-Mesenchymal Transition Pathway Abrogates Resistance to Anti-Folate Chemotherapy in Lung Cancer
Researchers showed that chemoresistance to pemetrexed, a multi-target anti-folate chemotherapeutic agent for non-small cell lung cancer, is associated with a stem cell-like phenotype characterized by an enriched stem cell gene signature, augmented aldehyde dehydrogenase activity and greater clonogenic potential. [Cell Death Dis] Full Article

Tungsten-Induced Carcinogenesis in Human Bronchial Epithelial Cells
A human bronchial epithelial cell line (Beas-2B) exposed to tungsten developed carcinogenic properties. In a soft agar assay, tungsten-treated cells formed more colonies than controls and the tungsten-transformed clones formed tumors in nude mice. [Toxicol Appl Pharmacol] Abstract

REV3L Modulates Cisplatin Sensitivity of Non-Small Cell Lung Cancer H1299 Cells
REV3L overexpression and silencing H1299 cell lines were established. Investigators showed that cisplatin induced the expression of REV3L by recruiting Sp1 to its promoter. [Oncol Rep] Abstract

MicroRNA-134 Regulates Lung Cancer Cell H69 Growth and Apoptosis by Targeting WWOX Gene and Suppressing the ERK1/2 Signaling Pathway
The authors investigated the pathogenic implications of miR-134 in small cell lung cancer (SCLC). Overexpression or inhibition MiR-134 expression by miR-134 mimics or miR-134 inhibitors in SCLC cell lines was detected using qRT-PCR. [Biochem Biophys Res Commun] Abstract

XCR1 Promotes Cell Growth and Migration and Is Correlated with Bone Metastasis in Non-Small Cell Lung Cancer
Researchers demonstrated for the first time that XCR1 was overexpressed in lung cancer bone metastasis as compared with that in patients with primary lung cancer. In addition, the XCR1 ligand XCL1 promoted the proliferation and migration of lung cancer cells markedly, and knockdown of XCR1 by siRNA abolished the effect of XCL1 in cell proliferation and migration. [Biochem Biophys Res Commun] Abstract

Watch Now: Webinar on Gastrointestinal Organoids by Dr. Meritxell Huch
 
REVIEWS
Epigenetics in Lung Fibrosis: From Pathobiology to Treatment Perspective
Idiopathic pulmonary fibrosis is a fatal disease with limited treatment options and extensive gene expression changes identified in the lung parenchyma. This review summarizes recent findings of association of DNA methylation and histone modifications with the presence of disease and fibroproliferation. [Curr Opin Pulm Med] Abstract

Visit our reviews page to see a complete list of reviews in the pulmonary cell research field.

4th Annual Excellence in Lung Cancer Screening & Continuum of Care
 
INDUSTRY NEWS
Memorial Sloan Kettering Launches New Lung Cancer Center Dedicated to Innovative Research
A new lung cancer research center has been created at Memorial Sloan Kettering Cancer Center. The Fiona and Stanley Druckenmiller Center for Lung Cancer Research is a multidisciplinary research initiative dedicated to developing innovative and more-effective treatments for people with lung cancer. [Memorial Sloan Kettering Cancer Center] Press Release

FDA Approves Targeted Therapy for First-Line Treatment of Patients with a Type of Metastatic Lung Cancer
The U.S. Food and Drug Administration (FDA) approved Iressa (gefitinib) for the first-line treatment of patients with metastatic non-small cell lung cancer whose tumors harbor specific types of epidermal growth factor receptor gene mutations, as detected by an FDA-approved test. [U.S. Food and Drug Administration] Press Release

apceth and University of Cologne to Join Forces on Combination Cellular Immunotherapies for Cancer
apceth announced a broad partnership with the Center for Molecular Medicine Cologne, University of Cologne, to combine technologies and expertise, on the development of immunotherapies for solid tumors and hematological malignancies. [apceth®] Press Release

From our sponsor: Culturing hematopoietic stem and progenitor cells? Download the technical bulletin.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW 2nd International Symposium of the Cancer Research Center of Lyon (CRCL)
September 21-23, 2015
Lyon, France

Visit our events page to see a complete list of events in the pulmonary cell community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Fellow – Cancer Research (National University of Singapore)

NEW Postdoctoral Training Fellow – Lung Cancer and Drug Resistance (Institute of Cancer Research)

Scientist – Pluripotent Stem Cell Biology Endoderm Lineages (STEMCELL Technologies Inc.)

PhD Studentships – Pulmonary Biology and Medicine (University of Giessen Lung Center)

Postdoctoral Fellow – Pulmonary Fibrosis (University of Colorado School of Medicine)

Assistant Professor – Neonatal Pulmonary Biology and Vascular Biology (Medical College of Wisconsin)

Senior Scientist – Stem Cells (Cystic Fibrosis Foundation)

Faculty Positions (Cleveland Clinic)

Research Scientist I/II – Fibrosis/Oncology/Inflammation Biology (Gilead Sciences)


Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Pulmonary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Pulmonary Cell News: Archives | Events | Contact Us